<DOC>
	<DOCNO>NCT01888354</DOCNO>
	<brief_summary>This pilot study design prospective cohort study determine whether standard subcutaneous ( SQ ) Highly-Purified ( HP ) Acthar Gel 14 day superior SQ HP Acthar Gel 5 day treatment relapse attack multiple sclerosis ( MS ) .</brief_summary>
	<brief_title>Pilot Clinical Trial ACTHar Gel 14 Days Subcutaneous ( SQ ) Versus ACTHar Gel Five Days SQ Treatment MS Exacerbations</brief_title>
	<detailed_description>Evaluations treatment administer outpatient Neurology Clinic . Each subject see MS relapse exacerbation Neurology Clinic routine semi-emergent visit . Patients offer FDA approve treatment ( ACTHar Gel ) MS attack standard 14 day SQ protocol ( standard 14 day SQ protocol ( 80 IU x 14 day ) 5 day SQ protocol - ( 5 day subcutaneous protocol ( 80 IU x 5 day ) . Both protocol within package insert guideline . The subject evaluate Extended Disability Status Scales ( EDSS ) , standardized measure clinical status MS initial visit 28 day later ( 90 day later ) . We compare change EDSS outcome day 0 day 28 ( day 90 ) determine 14 day superior 5 day protocol may clinically equivalent . Patients also evaluate walking , upper extremity function ( 9 hole peg test ) , cognition vision .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>1 . Adult male female subject MS relapse ( attack ) exacerbation MS . Acute symptomatic exacerbation MS present &gt; 24 hour &lt; 14 day screen new worsening symptom , sign referable symptom absence fever active infection . 2 . Diagnosis relapse form multiple sclerosis randomization determine Poser McDonald Criteria ( standard MS diagnostic criterion ) . 3 . Expanded disability status scale ( EDDS ) 2 6.5 , inclusive entry . 4 . Episodes include study neurologist neuroophthalmologist diagnose : acute optic neuritis , cerebellar , brainstem dysfunction , myelitis , focal cerebral , and/or definitive focal sensory dysfunction . 5 . New objective clinical find sensory exacerbation bowel/bladder sign alone . Sensory deficit alone qualify except optic neuritis . 6 . Subjects may continue current immunomodulation therapy interferon , glatiramer acetate , gilenya natalizumab . 7 . Identified patient must age 18 55 year , inclusive . 8 . Ability understand willingness sign write informed consent document . 1 . Subjects pregnant , nursing . 2 . Any patient treat systemic corticosteroid use within one month index episode screen . 3 . Prior use immunosuppressive treatment within 90 day index episode ( mitoxantrone , azathioprine , Cellcept , IVIg ) plasmapheresis . 4 . Unable perform time 25 foot walk ( ambulation Index ) , 9 HPT ( 9 hole peg test ) , PASAT ( Paced Auditory Serial Addition Test ) 3 . 5 . Peripheral cranial neuropathy sole problem acute episode . 6 . Subjects uncontrolled intercurrent illness include , limited ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . 7 . History significant cardiac , gastrointestinal , hepatic , pulmonary , renal disease ; immune deficiency ; medical condition would preclude corticosteroid therapy . 8 . Subjects clinical diagnosis scleroderma , osteoporosis , systemic fungal infection , ocular herpes simplex , recent surgery , history presence peptic ulcer , congestive heart failure , hypertension , sensitivity protein porcine origin . 9 . Primary Progressive Multiple Sclerosis ( PPMS ) ( MS without attack ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>MS</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>